Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 277

1.

CD44 deletion suppresses atypia in the precancerous mouse testis.

Li H, Shukla S, Frappart L, Herrlich P, Ploubidou A.

Mol Carcinog. 2018 Dec 23. doi: 10.1002/mc.22961. [Epub ahead of print]

PMID:
30582228
2.

Gamma secretase dependent release of the CD44 cytoplasmic tail upregulates IFI16 in cd44-/- tumor cells, MEFs and macrophages.

Schultz K, Grieger Lindner C, Li Y, Urbánek P, Ruschel A, Minnich K, Bruder D, Gereke M, Sechi A, Herrlich P.

PLoS One. 2018 Dec 12;13(12):e0207358. doi: 10.1371/journal.pone.0207358. eCollection 2018.

3.

Spindle Misorientation of Cerebral and Cerebellar Progenitors Is a Mechanistic Cause of Megalencephaly.

Li H, Kroll T, Moll J, Frappart L, Herrlich P, Heuer H, Ploubidou A.

Stem Cell Reports. 2017 Oct 10;9(4):1071-1080. doi: 10.1016/j.stemcr.2017.08.013. Epub 2017 Sep 21.

4.

ADAM Metalloprotease-Released Cancer Biomarkers.

Herrlich P, Herrlich A.

Trends Cancer. 2017 Jul;3(7):482-490. doi: 10.1016/j.trecan.2017.05.001. Epub 2017 May 25. Review.

PMID:
28718403
5.

Growth factor and co-receptor release by structural regulation of substrate metalloprotease accessibility.

Parra LM, Hartmann M, Schubach S, Ma J, Herrlich P, Herrlich A.

Sci Rep. 2016 Nov 23;6:37464. doi: 10.1038/srep37464.

6.

Impaired Planar Germ Cell Division in the Testis, Caused by Dissociation of RHAMM from the Spindle, Results in Hypofertility and Seminoma.

Li H, Frappart L, Moll J, Winkler A, Kroll T, Hamann J, Kufferath I, Groth M, Taudien S, Schütte M, Yaspo ML, Heuer H, Lange BM, Platzer M, Zatloukal K, Herrlich P, Ploubidou A.

Cancer Res. 2016 Nov 1;76(21):6382-6395. Epub 2016 Aug 19.

7.

Distinct Intracellular Domain Substrate Modifications Selectively Regulate Ectodomain Cleavage of NRG1 or CD44.

Parra LM, Hartmann M, Schubach S, Li Y, Herrlich P, Herrlich A.

Mol Cell Biol. 2015 Oct;35(19):3381-95. doi: 10.1128/MCB.00500-15. Epub 2015 Jul 27.

8.

Inside-out Regulation of Ectodomain Cleavage of Cluster-of-Differentiation-44 (CD44) and of Neuregulin-1 Requires Substrate Dimerization.

Hartmann M, Parra LM, Ruschel A, Lindner C, Morrison H, Herrlich A, Herrlich P.

J Biol Chem. 2015 Jul 10;290(28):17041-54. doi: 10.1074/jbc.M114.610204. Epub 2015 Apr 29.

9.

RHAMM deficiency disrupts folliculogenesis resulting in female hypofertility.

Li H, Moll J, Winkler A, Frappart L, Brunet S, Hamann J, Kroll T, Verlhac MH, Heuer H, Herrlich P, Ploubidou A.

Biol Open. 2015 Mar 6;4(4):562-71. doi: 10.1242/bio.201410892.

10.

Tumor Suppressor NF2 Blocks Cellular Migration by Inhibiting Ectodomain Cleavage of CD44.

Hartmann M, Parra LM, Ruschel A, Böhme S, Li Y, Morrison H, Herrlich A, Herrlich P.

Mol Cancer Res. 2015 May;13(5):879-90. doi: 10.1158/1541-7786.MCR-15-0020-T. Epub 2015 Feb 4.

11.

The LIM domain protein nTRIP6 recruits the mediator complex to AP-1-regulated promoters.

Diefenbacher ME, Reich D, Dahley O, Kemler D, Litfin M, Herrlich P, Kassel O.

PLoS One. 2014 May 12;9(5):e97549. doi: 10.1371/journal.pone.0097549. eCollection 2014.

12.

Novel mechanism of JNK pathway activation by adenoviral E1A.

Romanov VS, Brichkina AI, Morrison H, Pospelova TV, Pospelov VA, Herrlich P.

Oncotarget. 2014 Apr 30;5(8):2176-86.

13.

Regulation of Son of sevenless by the membrane-actin linker protein ezrin.

Geissler KJ, Jung MJ, Riecken LB, Sperka T, Cui Y, Schacke S, Merkel U, Markwart R, Rubio I, Than ME, Breithaupt C, Peuker S, Seifert R, Kaupp UB, Herrlich P, Morrison H.

Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20587-92. doi: 10.1073/pnas.1222078110. Epub 2013 Dec 2.

14.

The responsibility of the scientist. What can history teach us about how scientists should handle research that has the potential to create harm?

Herrlich P.

EMBO Rep. 2013 Sep;14(9):759-64. doi: 10.1038/embor.2013.116. Epub 2013 Aug 13. No abstract available.

15.

A link between two tumorigenic proteins, CD44 and p21WAF1: CD44 increases phorbol ester-induced expression of p21WAF1 by stabilizing its mRNA and extending protein half-life.

Lindner C, Urbánek P, Pavelka B, Hartmann M, Herrlich P.

FEBS Lett. 2013 Aug 19;587(16):2698-704. doi: 10.1016/j.febslet.2013.07.010. Epub 2013 Jul 12.

16.

Who decides when to cleave an ectodomain?

Hartmann M, Herrlich A, Herrlich P.

Trends Biochem Sci. 2013 Mar;38(3):111-20. doi: 10.1016/j.tibs.2012.12.002. Epub 2013 Jan 5. Review.

PMID:
23298902
17.

CD44 Promotes intoxication by the clostridial iota-family toxins.

Wigelsworth DJ, Ruthel G, Schnell L, Herrlich P, Blonder J, Veenstra TD, Carman RJ, Wilkins TD, Van Nhieu GT, Pauillac S, Gibert M, Sauvonnet N, Stiles BG, Popoff MR, Barth H.

PLoS One. 2012;7(12):e51356. doi: 10.1371/journal.pone.0051356. Epub 2012 Dec 7.

18.

Activation of Ras requires the ERM-dependent link of actin to the plasma membrane.

Sperka T, Geissler KJ, Merkel U, Scholl I, Rubio I, Herrlich P, Morrison HL.

PLoS One. 2011;6(11):e27511. doi: 10.1371/journal.pone.0027511. Epub 2011 Nov 21.

19.

The nuclear isoform of the LIM domain protein Trip6 integrates activating and repressing signals at the promoter-bound glucocorticoid receptor.

Diefenbacher ME, Litfin M, Herrlich P, Kassel O.

Mol Cell Endocrinol. 2010 May 14;320(1-2):58-66. doi: 10.1016/j.mce.2010.02.010. Epub 2010 Feb 12.

PMID:
20153803
20.

Calpain-mediated degradation of reversibly oxidized protein-tyrosine phosphatase 1B.

Trümpler A, Schlott B, Herrlich P, Greer PA, Böhmer FD.

FEBS J. 2009 Oct;276(19):5622-33. doi: 10.1111/j.1742-4658.2009.07255.x. Epub 2009 Aug 27.

21.

Restriction to Fos family members of Trip6-dependent coactivation and glucocorticoid receptor-dependent trans-repression of activator protein-1.

Diefenbacher M, Sekula S, Heilbock C, Maier JV, Litfin M, van Dam H, Castellazzi M, Herrlich P, Kassel O.

Mol Endocrinol. 2008 Aug;22(8):1767-80. doi: 10.1210/me.2007-0574. Epub 2008 Jun 5.

22.

Supreme EnLIGHTenment: damage recognition and signaling in the mammalian UV response.

Herrlich P, Karin M, Weiss C.

Mol Cell. 2008 Feb 15;29(3):279-90. doi: 10.1016/j.molcel.2008.01.001. Review.

23.

Crosstalk between the glucocorticoid receptor and other transcription factors: molecular aspects.

Kassel O, Herrlich P.

Mol Cell Endocrinol. 2007 Sep 15;275(1-2):13-29. Epub 2007 Jul 10. Review.

PMID:
17689856
24.

Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac.

Morrison H, Sperka T, Manent J, Giovannini M, Ponta H, Herrlich P.

Cancer Res. 2007 Jan 15;67(2):520-7.

25.

Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin.

Orian-Rousseau V, Morrison H, Matzke A, Kastilan T, Pace G, Herrlich P, Ponta H.

Mol Biol Cell. 2007 Jan;18(1):76-83. Epub 2006 Oct 25.

26.

Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase.

Jin H, Sperka T, Herrlich P, Morrison H.

Nature. 2006 Aug 3;442(7102):576-9.

PMID:
16885985
27.

A five-amino-acid peptide blocks Met- and Ron-dependent cell migration.

Matzke A, Herrlich P, Ponta H, Orian-Rousseau V.

Cancer Res. 2005 Jul 15;65(14):6105-10.

28.

Listeria monocytogenes exploits ERM protein functions to efficiently spread from cell to cell.

Pust S, Morrison H, Wehland J, Sechi AS, Herrlich P.

EMBO J. 2005 Mar 23;24(6):1287-300. Epub 2005 Feb 24.

29.

Investigation of protein-tyrosine phosphatases by in-gel assays.

Markova B, Gulati P, Herrlich PA, Böhmer FD.

Methods. 2005 Jan;35(1):22-7.

PMID:
15588982
30.

Towards dissecting the complexity of the AP-1 (activator protein 1) family.

Unal R, Weih F, Schorle H, Herrlich P.

Adv Exp Med Biol. 2004;553:331-6. No abstract available.

PMID:
15503467
31.

Genes upregulated in a metastasizing human colon carcinoma cell line.

Orian-Rousseau V, Mink S, Mengwasser J, HogenEsch H, Guo F, Thies WG, Hofmann M, Herrlich P, Ponta H.

Int J Cancer. 2005 Feb 20;113(5):699-705.

32.

A nuclear isoform of the focal adhesion LIM-domain protein Trip6 integrates activating and repressing signals at AP-1- and NF-kappaB-regulated promoters.

Kassel O, Schneider S, Heilbock C, Litfin M, Göttlicher M, Herrlich P.

Genes Dev. 2004 Oct 15;18(20):2518-28.

33.

UVA inactivates protein tyrosine phosphatases by calpain-mediated degradation.

Gulati P, Markova B, Göttlicher M, Böhmer FD, Herrlich PA.

EMBO Rep. 2004 Aug;5(8):812-7. Epub 2004 Jul 9. Erratum in: EMBO Rep. 2005 Nov;6(11):1101.

34.

Hyaluronan-oligosaccharide-induced transcription of metalloproteases.

Fieber C, Baumann P, Vallon R, Termeer C, Simon JC, Hofmann M, Angel P, Herrlich P, Sleeman JP.

J Cell Sci. 2004 Jan 15;117(Pt 2):359-67. Epub 2003 Dec 2.

35.
36.

Identification of protein tyrosine phosphatases associating with the PDGF receptor.

Markova B, Herrlich P, Rönnstrand L, Böhmer FD.

Biochemistry. 2003 Mar 11;42(9):2691-9.

PMID:
12614164
37.

CD44: from adhesion molecules to signalling regulators.

Ponta H, Sherman L, Herrlich PA.

Nat Rev Mol Cell Biol. 2003 Jan;4(1):33-45. Review.

PMID:
12511867
38.

Antagonistic signaling pathways regulate alternative splicing of CD44 in T cells.

Weg-Remers S, Ponta H, Herrlich P, König H.

Ann N Y Acad Sci. 2002 Nov;973:112-5. No abstract available.

PMID:
12485845
39.

Signal-dependent regulation of splicing via phosphorylation of Sam68.

Matter N, Herrlich P, König H.

Nature. 2002 Dec 12;420(6916):691-5.

PMID:
12478298
40.

CD44 is required for two consecutive steps in HGF/c-Met signaling.

Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H.

Genes Dev. 2002 Dec 1;16(23):3074-86.

41.

The anti-inflammatory action of glucocorticoid hormones.

Herrlich P, Göttlicher M.

Ernst Schering Res Found Workshop. 2002;(40):297-304. Review. No abstract available.

PMID:
12355722
42.

CD44 variant-specific antibodies trigger hemopoiesis by selective release of cytokines from bone marrow macrophages.

Khaldoyanidi S, Karakhanova S, Sleeman J, Herrlich P, Ponta H.

Blood. 2002 Jun 1;99(11):3955-61.

43.

Redox regulation in mammalian signal transduction.

Gulati P, Klöhn PC, Krug H, Göttlicher M, Markova B, Böhmer FD, Herrlich P.

IUBMB Life. 2001 Jul;52(1-2):25-8. Review. No abstract available.

44.

Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor.

Reichardt HM, Tuckermann JP, Göttlicher M, Vujic M, Weih F, Angel P, Herrlich P, Schütz G.

EMBO J. 2001 Dec 17;20(24):7168-73.

46.

Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway.

Weg-Remers S, Ponta H, Herrlich P, König H.

EMBO J. 2001 Aug 1;20(15):4194-203.

47.

Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid.

Ahrens T, Sleeman JP, Schempp CM, Howells N, Hofmann M, Ponta H, Herrlich P, Simon JC.

Oncogene. 2001 Jun 7;20(26):3399-408.

48.

Cross-talk between glucocorticoid receptor and AP-1.

Herrlich P.

Oncogene. 2001 Apr 30;20(19):2465-75. Review.

49.

The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44.

Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, Gutmann DH, Ponta H, Herrlich P.

Genes Dev. 2001 Apr 15;15(8):968-80.

50.

Gene expression patterns associated with the metastatic phenotype in rodent and human tumors.

Nestl A, Von Stein OD, Zatloukal K, Thies WG, Herrlich P, Hofmann M, Sleeman JP.

Cancer Res. 2001 Feb 15;61(4):1569-77.

Supplemental Content

Loading ...
Support Center